Rocuronium Fresenius 25 mg/2,5 ml; 50 mg/5 ml; 100 mg/10 ml Solution for injection or infusion.
PDF Leaflet Revision Date: 15 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to general anaesthesia for tracheal intubation and muscle relaxation.
Dosage (summary)
0.6 mg/kg for intubation; maintenance 0.15 mg/kg.
Onset of Action / Duration
Onset: 60-90 secs, Duration: 30-60 mins.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; limited placental transfer.
Key Drug Interactions
- Halogenated volatile anaesthetics
- Aminoglycosides
- Corticosteroids
Contraindications
- Hypersensitivity to rocuronium
- Neonates
Common side effects
- Injection site pain
- Hypersensitivity
- Tachycardia
Counselling Points
- Monitor for respiratory function
- Avoid driving for 24 hours post-recovery
- Report any allergic reactions
Serious warnings
- Risk of respiratory paralysis
- Anaphylactic reactions
- Residual neuromuscular blockade
Important Disclaimer
The Rocuronium Fresenius 25 mg/2,5 ml; 50 mg/5 ml; 100 mg/10 ml Solution for injection or infusion. professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
